This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

O. RESNICK, Ph.D.; M. HAGOPIAN, M.A.; H. HOAGLAND, Ph.D.; H. FREEMAN, M.D.

AMA Arch Gen Psychiatry 1960;2(4):459-461.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Previous work in this laboratory^1-5 has shown that when epinephrine labeled with C¹⁴ in the N-methyl group of the side-chain was infused, approximately one-third of the radioactivity was recovered in the urine. These data suggested the following conclusions: (1) Approximately two-thirds of the infused epinephrine lose the N-methyl group of the side-chain via the monoamine oxidase enzyme system (MAO), and (2) approximately one-third of the infused epinephrine retains the N-methyl group, of which 1%-5% represents epinephrine and its conjugate and the remainder represents metanephrine and its conjugate.

If a patient under therapy with a MAO inhibitor is infused with N-methyl-labeled epinephrine, more than one-third of the infused radioactivity should be recovered in the urine if the MAO is inhibited. The following information is thus obtained: 1. One may determine whether or not the compound is entering the blood stream in amounts sufficient . . . [Full Text PDF of this Article]

Author Affiliations
Shrewsbury, Mass.

Footnotes
Submitted for publication Oct. 8, 1959.

Worcester Foundation for Experimental Biology, Shrewsbury, Mass., and Medfield State Hospital, Medfield, Mass.

This investigation was aided in part by grants from the Ford Foundation, Hoffmann-LaRoche, Inc., and the U.S. Public Health Service (MY-2936).

Marplan, R05-0994, and Rimifon were generously supplied by Dr. Robert J. Floody, Assistant Medical Director, Hoffmann-LaRoche, Inc., Nutley 10, N.J.

This study was carried out under U.S. Atomic Energy Commission License No. 20-1225-2, Amendment No. 4, for clinical investigations of labeled epinephrine in man.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?